Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial

INTRODUCTION: Inflammation plays a critical role in the pathogenesis of atherosclerosis, the leading cause of ischaemic heart disease (IHD). Studies in preclinical models have demonstrated that an increase in regulatory T cells (Tregs), which have a potent immune modulatory action, led to a regressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sriranjan, Rouchelle, Zhao, Tian Xiao, Tarkin, Jason, Hubsch, Annette, Helmy, Joanna, Vamvaka, Evangelia, Jalaludeen, Navazh, Bond, Simon, Hoole, Stephen P, Knott, Philip, Buckenham, Samantha, Warnes, Victoria, Bird, Nick, Cheow, Heok, Templin, Heike, Cacciottolo, Paul, Rudd, James H F, Mallat, Ziad, Cheriyan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558794/
https://www.ncbi.nlm.nih.gov/pubmed/36207050
http://dx.doi.org/10.1136/bmjopen-2022-062602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558794/
https://www.ncbi.nlm.nih.gov/pubmed/36207050
http://dx.doi.org/10.1136/bmjopen-2022-062602

Ejemplares similares